Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Carcinosarcoma × Nivolumab × Clear all

Phase

Status

Active not recruiting 3 Unknown 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 22 Carcinoma, Non-Small-Cell Lung 22 Stomach Neoplasms 8 Neoplasms 6 Carcinoma, Renal Cell 6 Carcinoma, Hepatocellular 6 Breast Neoplasms 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Neoplasm Metastasis 4 Hodgkin Disease 4 Urinary Bladder Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Uveal Melanoma 2 Small Cell Lung Carcinoma 2 Sarcoma 2 Mesothelioma, Malignant 2 Lymphoma, B-Cell 2 Gastrointestinal Neoplasms 2 Esophageal Squamous Cell Carcinoma 2 Esophageal Neoplasms 2 Carcinoma, Transitional Cell 2 Carcinoma, Merkel Cell 2 Brain Neoplasms 2 Uterine Cervical Neoplasms 1 Urogenital Neoplasms 1 Thymoma 1

Interventions

Paclitaxel 2 olaparib 1 cediranib 1 apatinib 1 Taxes 1 Nivolumab 1 Ifosfamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05224999 2022-02-04

Nivolumab for Recurrent/Metastatic Carcinosarcoma

Yonsei University

Phase 2 Unknown

Carcinosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡